论文部分内容阅读
目的:探讨分析对于子宫内膜癌患者应用孕激素的治疗效果和其在医学领域的发展前景。方法:选取研究对象70例,将其随机平均分为治疗组和对照组,对照组给予米非司酮口服治疗,治疗组给予孕激素治疗。结果:治疗组治疗后与治疗前相比,雌激素受体(ER)、孕激素受体(PR)、增殖细胞核抗原(PCNA)、CD44拼构变异体6(CD44V6)含量较低,抗凋亡因子(Bax)含量较高;对照组治疗后与治疗前相比,ER、PR、PCNA、CD44V6含量较低,Bax含量较高,差异具有统计学意义(P<0.05);治疗组在接受治疗后,与对照组相比,病变消失比例较高,阴道出血、阴道排液比例较低,差异具有统计学意义(P<0.05);治疗组与对照组比较,总有效率较高,差异具有统计学意义(P<0.05)。结论:孕激素在子宫内膜癌患治疗过程中效果是比较乐观的,治疗后期的副作用表现较轻、使用起来安全可靠,值得在临床中展开全面的研究和应用。
Objective: To investigate the therapeutic effect of progestin on patients with endometrial cancer and its prospects in the medical field. Methods: Seventy patients were selected and randomly divided into treatment group and control group. The control group was treated with mifepristone orally, and the treatment group was treated with progestin. Results: The levels of estrogen receptor (ER), progesterone receptor (PR), proliferating cell nuclear antigen (PCNA) and CD44 variant 6 (CD44V6) in treatment group after treatment were lower than those before treatment, The content of Bax in the control group was higher than that in the control group before treatment. The levels of ER, PR, PCNA and CD44V6 in the control group were lower and the content of Bax was higher in the control group (P <0.05) After treatment, compared with the control group, lesions disappeared higher proportion of vaginal bleeding, vaginal discharge was lower, the difference was statistically significant (P <0.05); treatment group compared with the control group, the total effective rate was higher, the difference Statistically significant (P <0.05). Conclusions: The effect of progestin in the treatment of endometrial cancer is more optimistic. The side effects in the later stage of treatment are less severe, and it is safe and reliable to use. It is worth to carry out comprehensive research and application in clinic.